Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewsWire · 3 days ago
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmGuruFocus · Oct 12, 2026
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPRNewsWire · Oct 12, 2026
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS LawGuruFocus · Oct 11, 2026
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS LawBusiness Wire · Oct 11, 2026
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)GuruFocus · Sep 25, 2026Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.63 | -$0.75 | Miss |
| May 20, 2026 | -$0.59 | -$0.73 | Miss |
| Feb 6, 2026 | -$0.72 | -$0.61 | Beat |
| Nov 10, 2025 | -$0.72 | -$0.73 | Miss |
| Aug 11, 2025 | -$0.69 | -$0.60 | Beat |
| May 29, 2025 | -$0.71 | -$0.64 | Beat |